抗血栓剂诱导的出血:来自现实世界药监测研究的新见解
Kangyuan Guo1, Ganyi Wang2, Li Zhang1
1School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Expert opinion on drug safety
|March 18, 2024
概括
原始低分子量肝素显示出更高的出血风险,可能是由于滥用. 随着时间的推移,不同抗血栓剂的出血风险有所不同,华法林和克洛皮多格雷尔的风险下降,但阿尔特,纳德罗巴林和迪皮里达摩尔的风险增加.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 临床药理学 临床药理学
背景情况:
- 出血是与抗血栓剂相关的主要不良事件.
- 关于这些药物引起的出血发作时间的研究有限.
研究的目的:
- 分析与抗血栓剂相关的出血发作的时间.
- 识别特定的抗血栓药物,随着时间的推移具有明显的出血风险概况.
主要方法:
- 来自河南药物不良反应监测中心的药物不良反应报告的回顾性分析.
- 使用报告几率比率用于信号检测出血事件.
- 使用韦布尔分布来评估出血开始的时间.
主要成果:
- 原始低分子量肝素被确定为出血的积极信号.
- 出血模式各不相同:大多数药物是随机的,华法林和克洛皮多格雷尔随着时间的推移而下降,而阿尔特,纳德罗巴林和迪皮里达摩尔则增加.
- 观察到原始低分子量肝素有较高的出血风险,可能与不合理的使用有关.
结论:
- 原始低分子量肝素具有显著的出血风险,需要改进管理和使用准则.
- 了解出血风险的时间依赖性对于优化抗血栓治疗至关重要.
- 特定的抗血栓剂表现出不同的时间出血风险概况,为临床决策提供了信息.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
692
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
692
Disorders of Hemostasis
888
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
888
Esophageal Varices-II: Clinical Features and Management
66
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
66
Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Introduction to Hemostasis
7.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.6K


